Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Prellis Biologics is a Bio AI company focused on antibody drug discovery, with EXISβ’ as its core platform. By using 3D bioprinted lymph node organoids, LNOβ’, it reconstructs parts of the human immune response in vitro, then combines this with machine learning to discover and optimize fully human antibodies from the immune diversity of multiple donors. It is closer to a drug discovery platform and collaborative R&D service than a consumer-facing AI tool.
The platform workflow includes sourcing diverse human immune cells, constructing 3D bioprinted organoids, activating B cells, antibody sequencing, screening and selection, AI-guided screening, and AI optimization. The AI component mainly uses initial screening and characterization data to train models, predict which antibody sequences are most worth pursuing experimentally, and iteratively update the models with results from new rounds of wet-lab experiments. The website also mentions that generative AI can further optimize antibody properties. Its key selling points are improving hit rates for difficult targets such as GPCRs, achieving broad epitope coverage, and reducing the immunogenicity risk of fully human antibodies.
The website does not disclose any free trial, standard pricing, subscription fees, or API usage pricing. Judging from the βPartner with Usβ messaging and information about strategic collaborations with pharmaceutical companies, its model appears to be mainly project-based collaboration, joint discovery, or pipeline partnerships, rather than self-service SaaS.
Its strengths lie in forming a closed loop between in vitro simulation of the human immune system, wet-lab validation, and AI models, which in theory makes it more grounded in biological experimentation than purely computational screening. The use of multiple donors also helps expand antibody diversity. The limitations are that public information is largely promotional, with little detail on model architecture, success rates, independent benchmarks, clinical translation outcomes, or data compliance. Ordinary companies also cannot simply sign up and use it the way they would with a conventional AI tool.
It is suitable for pharmaceutical companies, biotech firms, and antibody R&D teams working on early-stage antibody discovery, difficult target screening, and candidate molecule optimization. The website does not specify access conditions from China. Network connectivity, cross-border sample handling, data compliance, and payment methods all need to be confirmed separately. Comparable companies in this general area include Absci, Generate:Biomedicines, AbCellera, Cradle Bio, and others.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on prellisbio.com official site.
prellisbio.com is an United States AI Apps provider. TG4G tracks its product information, an overall rating of 8.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach prellisbio.com directly.